Kerstin Papenfuss, PhD, Director, Pharma, Deep Science Ventures, looks at the unmet need for fibrosis treatments and where drug discovery opportunities lay in terms of treatment and technology. Fibrosis is a complex pathological process characterised by excessive accumulation of extracellular matrix (ECM) components, particularly collagen, in response to chronic tissue damage. This process can affect […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!